FDA OKs Repotrectinib in NTRK Gene Fusion-Positive Solid Tumors
 |
|
BREAKING NEWS
|
| FDA OKs Repotrectinib in NTRK Gene Fusion-Positive Solid Tumors Patients 12 years and older with NTRK gene fusion-positive solid tumors may now receive repotrectinib. |
|